keyword
MENU ▼
Read by QxMD icon Read
search

Carcinoma cells renal

keyword
https://www.readbyqxmd.com/read/28213859/recurrence-in-localized-renal-cell-carcinoma-a-systematic-review-of-contemporary-data
#1
REVIEW
Jacqueline M Speed, Quoc-Dien Trinh, Toni K Choueiri, Maxine Sun
PURPOSE OF REVIEW: Patients with localized renal cell carcinoma (RCC) are at risk of recurrence. The purpose of this review was to characterize the literature on recurrence rates and risk factors after diagnosis of localized RCC. RECENT FINDINGS: Our search revealed that existing data examining the prevalence of recurrence rates predominantly originates from cohorts of patients diagnosed and treated in the 1980s to 1990s, and may therefore not be as useful for counseling for current patients today...
February 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28213730/impact-of-baseline-visceral-fat-accumulation-on-prognosis-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-systemic-therapy
#2
Ryuichi Mizuno, Akira Miyajima, Taizo Hibi, Aya Masuda, Toshiaki Shinojima, Eiji Kikuchi, Masahiro Jinzaki, Mototsugu Oya
The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm(2). The mean visceral fat area was 107...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28213366/tumor-infiltrating-and-peripheral-blood-t-cell-immunophenotypes-predict-early-relapse-in-localized-clear-cell-renal-cell-carcinoma
#3
Nicolas A Giraldo, Etienne Becht, Yann Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sanchez-Salas, Alexandre Ingels, Stephane Marie Oudard, Audrey Moatti, Bénédicte Buttard, Sarah Bourras, Claire Germain, Xavier Cathelineau, Wolf-Herman Fridman, Catherine Sautes-Fridman
PURPOSE: The efficacy of PD-1 Checkpoint Blockade (ChB) as adjuvant therapy in localized clear cell Renal Cell Carcinoma (ccRCC) is currently unknown. The identification of tumor microenvironment (TME) prognostic biomarkers in this setting may help to define which patients could benefit from ChB and to uncover new therapeutic targets. EXPERIMENTAL DESIGN: We performed multiparametric flow cytometry immunophenotypic analysis of T cells isolated from tumor tissue (TIL), adjacent non-malignant renal tissue (RIL) and peripheral blood (PBL), in a cohort of patients (n=40) with localized ccRCC...
February 17, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28212853/long-term-survival-after-resection-of-sentinel-node-metastatic-renal-cell-carcinoma
#4
Teele Kuusk, Jeroen De Jong, Nikolaos Grivas, Simon Horenblas, Axel Bex
We present a case of a patient who took part in a prospective sentinel lymph node (SN) study to investigate the drainage pattern from renal tumors. The patient was treated with laparoscopic radical nephrectomy (LRN), SN and non-SN lymph node dissection (LND) for a clinically node negative (cN0) left renal tumor of 6 cm (cT1b). Histopathological examination revealed a papillary type 2 pT1b renal cell carcinoma (RCC) with two para-aortic metastatic SNs (pN1). No adjuvant treatment was applied. The patient is free of disease at 63 months after surgery...
February 14, 2017: Urology
https://www.readbyqxmd.com/read/28212566/genetic-characterization-of-polish-ccrcc-patients-somatic-mutation-analysis-of-pbrm1-bap1-and-kdmc5-genomic-snp-array-analysis-in-tumor-biopsy-and-preliminary-results-of-chromosome-aberrations-analysis-in-plasma-cell-free-dna
#5
Katarzyna Kluzek, Malgorzata I Srebniak, Weronika Majer, Agnieszka Ida, Tomasz Milecki, Kinga Huminska, Robert M van der Helm, Adrian Silesian, Tomasz M Wrzesinski, Jacek Wojciechowicz, Berna H Beverloo, Zbigniew Kwias, Hans A R Bluyssen, Joanna Wesoly
BACKGROUND: Mutation analysis and cytogenetic testing in clear cell renal cell carcinoma (ccRCC) is not yet implemented in a routine diagnostics of ccRCC. MATERIAL AND METHODS: We characterized the chromosomal alterations in 83 ccRCC tumors from Polish patients using whole genome SNP genotyping assay. Moreover, the utility of next generation sequencing of cell free DNA (cfDNA) in patients plasma as a potential tool for non-invasive cytogenetic analysis was tested...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28212559/the-selective-mek1-inhibitor-selumetinib-enhances-the-antitumor-activity-of-everolimus-against-renal-cell-carcinoma-in-vitro-and-in-vivo
#6
Yun Zou, Jianfeng Wang, Xuejiao Leng, Jiwei Huang, Wei Xue, Jin Zhang, Yiran Huang
Renal cell carcinoma (RCC) is a urologic malignant cancer and often diagnosed at an advanced stage, which results in high mortality. Targeted therapy may improve the quality of life and survival of patients who are not suitable for nephrectomy. Everolimus, an mTOR inhibitor, is currently used as sequential or second-line therapy for RCC refractory to Sunitinib or sorafenib. However, its efficiency is palliative. In this study, we evaluated whether the antitumor activity of everolimus against RCC is enhanced by Selumetinib, a selective MEK1 inhibitor...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28212363/vegf-inhibitors-in-renal-cell-carcinoma
#7
Pankit Vachhani, Saby George
The arrival of targeted therapies-vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors-and programmed death 1 (PD-1) inhibitors has transformed the management of renal cell carcinoma (RCC). Once considered fatal, with a median survival of approximately 1 year, these agents have nearly tripled overall survival and have raised hopes of a possible cure for advanced RCC. This review begins with a brief discussion of the seminal von Hippel-Lindau/hypoxia-inducible factor axis in RCC...
December 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28211281/jejunal-metastasis-of-renal-cell-carcinoma
#8
Pamela Estévez Boullosa, Alfonso Martínez Turnes, Roberto Carracedo Iglesias, José Ignacio Rodríguez Prada
A 71-year-old female presented with melena and anemia. She had a past medical history of renal cell carcinoma diagnosed six years earlier and treated with left nephrectomy. Gastroscopy and colonoscopy showed no abnormalities. Renal cell carcinoma (RCC) is the third commonest urological malignancy, and approximately 25-50% of patients develop metastatic disease after surgery of the primary tumor. The most common sites of metastasis involve lung, lymph nodes, liver, bone and adrenal glands.
February 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28211006/surgical-margins-in-nephron-sparing-surgery-for-renal-cell-carcinoma
#9
REVIEW
Dean D Laganosky, Christopher P Filson, Viraj A Master
The oncologic impact of positive surgical margins after nephron-sparing surgery is controversial. Herein, we discuss current data surrounding surgical margins in the operative management of renal cell carcinoma. The prevalence, risk factors, outcomes, and subsequent management of positive surgical margins will be reviewed. Literature suggests that the prevalence of positive surgical margins following kidney surgery varies by practice setting, tumor characteristics, and operation type. For patients undergoing nephron-sparing surgery, it is not necessary to remove a margin of healthy tissue...
January 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28210995/checkpoint-inhibitors-for-the-treatment-of-renal-cell-carcinoma
#10
REVIEW
Pooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, Elizabeth R Plimack
The advent of checkpoint inhibitors has revolutionized systemic therapy for many malignancies, including renal cell carcinoma (RCC) where multiple PD-1, PD-L1, and CTLA-4 inhibitors have demonstrated responses and improved survival for patients in clinical trials. Durable benefit with manageable toxicity can be achieved with these agents-but unfortunately for only a minority of individuals. Efforts are ongoing to understand mechanisms driving the response and resistance to checkpoint inhibitors in order to personalize therapy and extend benefit to more patients...
January 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28210496/the-additional-utility-of-apparent-diffusion-coefficient-values-of-clear-cell-renal-cell-carcinoma-for-predicting-metastasis-during-clinical-staging
#11
Rika Yoshida, Takeshi Yoshizako, Araki Hisatoshi, Hiroshi Mori, Yukihisa Tamaki, Noriyoshi Ishikawa, Hajime Kitagaki
BACKGROUND: The apparent diffusion coefficient (ADC) value is known to be an indicator of tumor activity. The ADC value of high-grade clear-cell renal cell carcinoma (RCC) is significantly lower than that of low-grade clear-cell RCC. PURPOSE: To investigate the utility of ADC values of clear-cell RCC by comparing ADC values between groups with T1a RCC (tumor size ≤ 4 cm) without metastasis and the group with metastasis. MATERIAL AND METHODS: A retrospective review was performed on 51 patients with 51 RCCs who underwent 1...
January 2017: Acta Radiologica Open
https://www.readbyqxmd.com/read/28209953/-extracorporeal-partial-nephrectomy-under-pharmaco-cold-ischemia-for-renal-cell-carcinoma
#12
A A Gritskevich, I V Miroshkina, S S Piyanikin, Z A Adyrkhayev, Yu A Stepanova, A E Zotikov, A A Teplov, V A Kubyshkin, A Sh Revishvili
AIM: To develop the method for extracorporeal partial nephrectomy under pharmaco-cold ischemia without ureter intersection with orthotopic replantation of renal vessels for RCC. MATERIAL AND METHODS: The study included 37 patients with morphologically confirmed RCC pT1a-Т3bN0M0-1G1-3 with intraparenchymal and central location of the tumor in cases of single kidney, comorbidity of contralateral kidney and kidney on the side of lesion. RESULTS: Mean surgery time was 413...
2017: Khirurgiia
https://www.readbyqxmd.com/read/28209559/irreversible-electroporation-for-the-ablation-of-renal-cell-carcinoma-a-prospective-human-in-vivo-study-protocol-ideal-phase-2b
#13
Mara Buijs, Krijn P van Lienden, Peter Gk Wagstaff, Matthijs Jv Scheltema, Daniel M de Bruin, Patricia J Zondervan, Otto M van Delden, Ton G van Leeuwen, Jean Jmch de la Rosette, M Pilar Laguna
BACKGROUND: Irreversible electroporation (IRE) is an emerging technique delivering electrical pulses to ablate tissue, with the theoretical advantage to overcome the main shortcomings of conventional thermal ablation. Recent short-term research showed that IRE for the ablation of renal masses is a safe and feasible treatment option. In an ablate and resect design, histopathological analysis 4 weeks after radical nephrectomy demonstrated that IRE-targeted renal tumors were completely covered by ablation zone...
February 16, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28208928/pulsatile-clavicular-swelling-as-the-sole-presentation-of-asymptomatic-renal-cell-carcinoma-with-an-isolated-metastasis-to-the-clavicle-a-case-report
#14
Ashwani Kumar, Nitish Arora, Paras Kumar Pandove, Garima Anand, Bharti Arora
Renal Cell Carcinoma (RCC) is notorious for its unpredictable dissemination patterns involving both lymphatic and haematogenous route without a clear-cut preponderance for any. Unlike other intra-abdominal malignancies like colorectal carcinoma, renal cell carcinoma is often known to metastasize to distant sites even after a confident and unsuspecting curative resection or often as the primary presentation constantly adding and agitating our presentation patterns for this sneaky tumour. Presented below is a case of such an unsuspecting female patient...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28208513/re-salvage-percutaneous-cryoablation-for-locally-recurrent-renal-cell-carcinoma-after-primary-cryoablation
#15
Jeffrey A Cadeddu
No abstract text is available yet for this article.
March 2017: Journal of Urology
https://www.readbyqxmd.com/read/28208511/re-first-line-sunitinib-versus-pazopanib-in-metastatic-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium
#16
https://www.readbyqxmd.com/read/28208226/a-rare-case-of-tfe-related-pigmented-renal-tumor-with-overlapping-features-between-melanotic-xp11-translocation-renal-cancer-and-xp11-renal-cell-carcinoma-with-melanotic-features
#17
Leonardo Cardili, Gregório Wrublevsky Pereira, Cristiano Ribeiro Viana
In recent years, an increasing number of TFE3 rearrangement-associated tumors with melanotic features have been reported as primary neoplasm in different anatomical sites, including the kidney. Melanotic Xp11 translocation renal cancer (MXTRC) and Xp11 renal cell carcinoma with melanotic features (XRCCM) have been proposed to be main categories for pigmented lesions in the microophthalmia-associated transcription factor (MiTF/TFE3) family of renal tumors that may show variable degrees of melanocytic differentiation...
February 16, 2017: Pathology International
https://www.readbyqxmd.com/read/28208153/outcome-of-patients-with-renal-cell-carcinoma-and-multiple-glandular-metastases-treated-with-targeted-agents
#18
Paolo Grassi, Ludovic Doucet, Palma Giglione, Viktor Grünwald, Bohuslav Melichar, Luca Galli, Ugo De Giorgi, Roberto Sabbatini, Cinzia Ortega, Matteo Santoni, Aristotelis Bamias, Elena Verzoni, Lisa Derosa, Hana Studentova, Luca Porcu, Filippo De Braud, Camillo Porta, Giuseppe Procopio
PURPOSE: Pancreatic metastases (PM) from renal cell carcinoma (RCC) have been associated with long-term survival. The aim of this study was to evaluate the outcome of RCC patients with multiple glandular metastases (MGM) treated with targeted therapies (TTs). METHODS: Sixty-four MGM patients treated between 1993 and 2014 were retrospectively identified from a database of 274 RCC patients with PM from 11 European centers. The survival of MGM patients was compared with that of both patients with PM only and a cohort of 325 RCC patients with non-GM (control group) treated with TTs...
February 17, 2017: Oncology
https://www.readbyqxmd.com/read/28205397/pancreatic-involvement-by-metastasizing-neoplasms-as-determined-by-endoscopic-ultrasound-guided-fine-needle-aspiration-a-clinicopathologic-characterization
#19
Miroslav Sekulic, Khalid Amin, Tetyana Mettler, Lizette K Miller, Shawn Mallery, Jimmie Stewart
BACKGROUND: Pancreatic tumors often represent primary neoplasms, however organ involvement with metastatic disease can occur. The use of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) to determine the underlying pathology provides guidance of clinical management. METHODS: 25 cases were identified in a retrospective review of our institution's records from 2006 to 2016. Clinical parameters and prognosis are described. RESULTS: Metastatic lesions to the pancreas diagnosed by EUS-FNA accounted for 4...
February 16, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/28205224/muc13-overexpression-in-renal-cell-carcinoma-plays-a-central-role-in-tumour-progression-and-drug-resistance
#20
Yonghua Sheng, Choa Ping Ng, Rohan Lourie, Esha T Shah, Yaowu He, Kuan Yau Wong, Inge Seim, Iulia Oancea, Christudas Morais, Penny L Jeffery, John Hooper, Glenda C Gobe, Michael A McGuckin
Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective. Here we reveal that MUC13, a cell surface mucin glycoprotein, is aberrantly expressed by most renal cell carcinomas, with increasing expression positively correlating with tumor grade. Importantly, we demonstrated that high MUC13 expression was a statistically significant independent predictor of poor survival in two independent cohorts, particularly in stage 1 cancers...
February 16, 2017: International Journal of Cancer. Journal International du Cancer
keyword
keyword
116101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"